Table 2.
Demographic and clinical aspects of the selected studies
| Ref. | n | Age | Male gender (%) | waiting time (mo) | MELD | Underlying disease | Major lesion diam (cm) | Number lesions | MC-OUT (%) | AFP ≥ 200 ng/mL (%) | LRT (%) | Cut-off | AUROC | > cut-off (%) | Recurr (%) | 5-yr TFS |
| Xia et al[24] | 343 | 49 ± 10 | 308 (90) | NA | 13 ± 6 | HBV = 320 | > 5:110 | > 3:91 | 199 (58) | 165 (48) | 222 (65) | 150 | 0.63 | 33 (10) | NA | < 150: 52 |
| Other = 23 | ≥ 150:25 | |||||||||||||||
| Lai et al[25] | 146 | 58 (54-63) | 116 (80) | 8 (3-10) | 11 (8-11) | HCV = 63 | 2.5 (1.7-3.5) | 1 (1-2) | 32 (22) | 8 (6) | 136 (93) | 150 | 0.66 | 28 (19) | 14 (10) | < 150:92 |
| HBV = 26 | ≥ 150:81 | |||||||||||||||
| Other = 57 | ||||||||||||||||
| Parisi et al[26] | 150 | 54 ± 7 | 125 (83) | 2 (0-12) | NA | HCV = 60 | 2.7 | 1 | 0 (-) | 13 (9) | 71 (47) | 150 | NA | 17 (11) | 19 (13) | NA |
| HBV = 34 | ||||||||||||||||
| Other = 56 | ||||||||||||||||
| Nicolini et al[27] | 70 | 57 (51-62) | 62 (89) | NA | 11 (7-15) | HCV = 41 | 1.3 (0.0-2.1) | 1 (0-2) | 12 (17) | 6 (9)1 | 70 (100) | 150 | NA | 5 (7) | 8 (11) | < 150:89 |
| HBV = 15 | ≥ 150:50 | |||||||||||||||
| Other = 14 | ||||||||||||||||
| Harimoto et al[28] | 190 | ≥ 59:97 | 107 (56) | NA | ≥ 15:60 | HCV = 134 | > 5:8 | > 3:41 | 66 (35) | 30 (16)2 | NA | 70.4 | 0.70 | 97 (51) | 28 (15) | < 70.4:95 |
| Other = 56 | ≥ 70.4:76 |
1
AFP ≥ 400 ng/mL;
2
AFP ≥ 300 ng/mL. MELD: Model for end-stage liver disease; MC: Milan Criteria; AFP: Alpha-fetoprotein; LRT: Locoregional treatment; AUROC: Area under the receiver operator curve; TFS: Tumor-free survival; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NA: Not available.